ReviewBMC infectious diseases2025
Non-genitourinary Ureaplasma urealyticum infections in solid organ transplant recipients: a case report and literature review.
Review in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUreaplasma urealyticum, a commensal organism, is potentially pathogenic. In solid organ transplant recipients, non-genitourinary U. urealyticum infection is associated with an increased risk of graft failure or death.
resultsWe reported a case of mediastinitis caused by U. urealyticum in a heart transplant recipient and reviewed 13 other cases previously described. Among the 14 patients, 3 were female and 11 were male, with a median age of 61 years. The median time to symptom onset was 9 days after surgery. Among the 10 documented cases with reported symptoms, altered mental status and hyperammonemia syndrome occurred in 9 cases, whereas our patient manifested persistent fever. Both culture and molecular diagnostics were employed in the reviewed cases, with molecular methods predominating. U. urealyticum was difficult to cover with initial empirical antibiotic therapy; the patient in this study improved after omadacycline antimicrobial therapy and was successfully discharged following subsequent management. Regarding clinical outcomes, four patients died or withdrew from treatment, while targeted therapy duration among surviving patients ranged from 9 days to 4 weeks.
conclusionsThere is a possibility of severe U. urealyticum infection in patients with immunodeficiency after organ transplantation. Monitoring ammonia levels, utilizing rapid diagnostics, and initiating prompt treatment are all crucial to improving prognosis and reducing severe nerve damage, organ dysfunction, and mortality. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.